Contents:

DATAMONITOR HEALTHCARE CONTACT DETAILS Scope Datamonitor Insight into the Female Cancer Market The negative impact of existing treatments for female cancer on the long term fertility and sterility of patients is a major unmet need in the female cancer market. Opportunities exist for companies to either develop cancer treatments which do not have these side effects, or to develop adjunctive treatments for cancer patients with long term fertility and/or sterility problems Growing emphasis on screening and awareness for female cancers will expand opportunities for treatments targeted at early stage patients. Companies developing products aimed at this segment of the market will need to develop drugs with mild side effect profiles and simple dosing regimens, if physicians and patients are to select these pharmacological treatments over surgical or radiation alternatives. The paucity of available clinical trial data for most gynecological cancers means that gold standard treatments have not been universally established and uptake of new drugs is slow. The opportunity exists for companies operating in other cancer markets to conduct small scale clinical trials highlighting the efficacy of their drugs in gynecological cancer patients, either in support of off-label use or a line extension strategy, or as a low-cost strategy of expanding the patient potential of their products. The growing importance of the gynecological oncologist specialty will necessitate new sales and marketing strategies for companies targeting these cancer types. Companies will not be able to rely on the clinical experience which oncologists have traditionally applied from larger tumor types to smaller gynecological cancers. Gynecological oncologists will need to be targeted with clinical trial and product information specific to the patient group they are treating via forums which are readily accessible to this specialty. Key Metrics DEFINITION AND EPIDEMIOLOGY Definitions Breast Cervical Endometrial Gestational trophoblastic disease Ovarian Uterine Sarcoma Vaginal Vulvar Epidemiology Incidence by age Incidence by region Mortality by region DIAGNOSIS AND TREATMENT Physicians involved in the care of female cancer patients USA Europe Japan Presentation Screening Cervical Breast Other Cancers Diagnosis and Staging Treatment Options Pharmacological therapy Cytotoxic therapy Hormonal therapy Innovative therapy Key factors influencing treatment decisions Treatment modalities Survival/Prognosis Side effects of treatment Fertility Sexuality MARKET ANALYSIS Product performance Regional analysis Global players Environmental Factors Generics Competition Pharmacoeconomics Harmonized Approval Awareness Pricing and Reimbursement COMPANY STRATEGIES A strong Women's Health presence Development of a broad product portfolio Case study: BMS's cytotoxic portfolio Pursuit of line extensions for marketed products Case study: Taxol Cultivation of off-label use Sustaining market share upon patent expiration Case study: AstraZeneca and Barr's distribution agreement Formation of R&D Licensing Agreements Out-licensing In-licensing Formation of development agreements with other players Case study-Roche's continued development of Herceptin Portfolio promotion via disease management Boosting of product performance through reformulations Case study-the launch of Zoladex LA Penetration of 'niche' markets with the assistance of orphan drug status US Japan Europe FUTURE OUTLOOK Unmet needs in treatment Efficacy Side Effects Compliance Proven Efficacy R&D pipeline Breast cancer Faslodex IMC-C225 Gemzar Theratope Evista Ovarian cancer ZD0473 Rubitecan Taxotere Cervical cancer MARKET FORECASTS 2001-2008 Epidemiology forecasts Sales forecasts Key events driving the female cancer market Expansion of existing classes: cytotoxics and monoclonal antibodies Increase in the prevalence of cancer New drug classes: angiogenesis inhibitors and gene therapies Global cost-containment measures Reformation of Medicare Patent expiries Awareness campaigns Disease management Increasing participation of older adults in clinical trials Trends in the female cancer market by segment Sales forecasts Key events driving the female cancer market by segment Drug life cycle Patent expiries Launch of novel cytotoxic therapies New hormonal therapy launches Competition from the innovative therapies Price cuts in Japan Expansion of existing innovative classes: monoclonal antibodies and therapeutic vaccines New innovative drug classes: angiogenesis inhibitors and gene therapies Forecasts of key female cancer products APPENDIX Risk factors for female cancers Breast Cervical Endometrial Gestational trophoblastic disease Ovarian Uterine sarcoma Vaginal cancer Vulvar Symptoms and diagnostic procedures Breast Cervical Endometrial Ovarian Gestational Trophoblastic Disease Uterine sarcoma Vaginal Vulvar Forecast Methodology Predicting market share Forecasting future growth Female Cancer market growth Female Cancer drug class growth Individual product growth Forecasting Drug Launches for Pipeline Drugs Global highest stage of development Research Programme Methodology SPRINT databases Primary Research List of Tables List of Figures